{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:57Z","timestamp":1791335637605,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP B88F12000730005"],"award-info":[{"award-number":["CUP B88F12000730005"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PON03PE_00146_1\/10 BIBIOFAR"],"award-info":[{"award-number":["PON03PE_00146_1\/10 BIBIOFAR"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jtho.2016.07.033","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T05:24:14Z","timestamp":1472016254000},"page":"1993-2005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Malignant Mesothelioma Effusions Are Infiltrated by\u00a0CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti\u2013PD-L1 Antibody Avelumab"],"prefix":"10.1016","volume":"11","author":[{"given":"Swati","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Abate-Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Guadagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.07.033_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.98.12040972","article-title":"Malignant pleural mesothelioma","volume":"12","author":"Boutin","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2016.07.033_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.07.033_bib4","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.07.033_bib5","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.07.033_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-5002(98)00014-2","article-title":"Sera from patients with malignant mesothelioma can contain autoantibodies","volume":"20","author":"Robinson","year":"1998","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.07.033_bib7","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.jtho.2016.07.033_bib8","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2016.07.033_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged\u00a0survival in epithelioid malignant pleural mesothelioma\u00a0patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2016.07.033_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-5002(00)00217-8","article-title":"Localised spontaneous regression in mesothelioma\u2014possible immunological mechanism","volume":"32","author":"Robinson","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.07.033_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib14","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Tansl Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib15","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.07.033_bib18","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/jco.2014.32.15_suppl.3064","article-title":"Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in adavnced solid malignancies","volume":"32","author":"Heery","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.07.033_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc gamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2016.07.033_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the\u00a0diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2016.07.033_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-1759(01)00359-3","article-title":"A\u00a0novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity","volume":"253","author":"Lecoeur","year":"2001","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jtho.2016.07.033_bib22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.07.033_bib23","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.07.033_bib24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/leu.2013.261","article-title":"Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway","volume":"28","author":"Ahmad","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtho.2016.07.033_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/cmi.2010.28","article-title":"Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer","volume":"7","author":"Zhang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jtho.2016.07.033_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses\u00a0in\u00a0vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.07.033_bib27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.07.033_bib28","doi-asserted-by":"crossref","first-page":"CT103","DOI":"10.1158\/1538-7445.AM2015-CT103","article-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028","volume":"75","author":"Alley","year":"2015","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.07.033_bib29","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jtho.2016.07.033_bib30","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/S0959-8049(16)31751-8","article-title":"Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: a phase 1B trial","volume":"51","author":"Hassan","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2016.07.033_bib31","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor\u00a0cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2016.07.033_bib32","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex\u00a0vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.07.033_bib33","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.07.033_bib34","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.07.033_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.jtho.2016.07.033_bib36","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.07.033_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.07.033_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2016.07.033_bib39","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416308401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416308401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T20:40:18Z","timestamp":1657744818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416308401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1556086416308401"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.07.033","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Mesothelioma Effusions Are Infiltrated by\u00a0CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti\u2013PD-L1 Antibody Avelumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}